Andrew Coles’ Post

At Sciety, our goal is to help our portfolio companies reach their full potential. We are here to support their growth, whether it be through introductions to potential customers, partners and team members, or operational and strategic advice. To learn more about what a partnership with Sciety can be like, read our recent interview with Christopher Aulin, CEO of our portfolio company Capitainer. Take a look at how Capitainer strengthened their market position, achieved a fully subscribed share issue in just two days, and expanded strategically into the US market – through a strategic collaboration with Sciety. Read the full story here: https://lnkd.in/dDiA2s9F #Sciety #Capitainer #VentureCapital

🔔 REMINDER: Somnus Investors meeting Location: Bath Date: 23rd February Open to: anyone who is interested in Somnus and thinking about investing Come and hear from and meet the team. Our investors come from three main backgrounds: ➡45 doctors who recognise the need for the products we are developing and are eager to use them day to day ➡Angels who investor in medtech or life science companies A cornerstone investor; an Emerging Markets Investment Trust, listed on the ➡Main Market of the London Stock Exchange. There will be presentations about the progress Somnus is making and the plans the Directors have for accessing key markets in the near future. There will also be opportunities to talk to a range of existing investors, as well as a Q&A with the senior team and the Advisory Board. #medtech #investmentopportunity

Congratulations to the ℝ𝕖𝕒𝕝 𝔻𝕖𝕒𝕝𝕤 𝗣𝗿𝗶𝘃𝗮𝘁𝗲 𝗘𝗾𝘂𝗶𝘁𝘆 𝗔𝘄𝗮𝗿𝗱𝘀 𝟮𝟬𝟮𝟰 𝘿𝙚𝙖𝙡 𝘼𝙬𝙖𝙧𝙙𝙨 𝙒𝙞𝙣𝙣𝙚𝙧𝙨 🏆 Central and Eastern European Deal of the Year: Enterprise Investors for Unilink 🏆 DACH Deal of the Year: Oakley Capital for IU Group 🏆 France and Benelux Deal of the Year: ARCHIMED for Polyplus 🏆 Mediterranean Deal of the Year: Wise Equity for Cantiere del Pardo S.p.A. 🏆 Nordic Deal of the Year: Norvestor for Kabal 🏆 UK Small-Cap Deal of the Year (EV on entry less than €25m): AURELIUS for Distrelec 🏆 UK Lower Mid-Cap Deal of the Year (EV on entry of €25-100m): Palatine for Anthesis Group 🏆 UK Upper Mid-Cap Deal of the Year (EV on entry of €100m+): Equistone Partners Europe for Acuity Knowledge Partners

Every year in March, Division 1 college basketball’s March Madness begins. 68 men’s teams and 68 women’s teams compete in their respective tournaments to be the national champions. With the Final Four coming up this weekend, we take a look at some of the critical success factors that can determine a win.   Every day, TriRadial helps emerging and mid-size biotech companies grow and scale. One of the ways we can help is by doing a Gap Analysis – to identify the People, Process, and Technology solutions needed for that company to score a win. We analyze resourcing, processes, digital solutions, and vendors to ensure successful outcomes.   Teams across the country strategize all year for how to emerge a March Madness champion. Reach out to see how TriRadial can help give your organization the winning plays to navigate your growth and ensure success in a fit-for-purpose roadmap. info@triradial.com #biotech #lifesciences #outsourcing #compliance #safety #quality #CROselection #GapAnalysis #triradial

Thanks for all the inquiries! I know every investor has different goals and even the same investor may want to achieve multiple objectives with their investment dollars. For those reasons we have multiple options: 🌟 Medinvest 1 LLC: Partnering with Rastegar Property Company for the development of a luxury high-rise at 1899 McKinney Ave, Dallas TX. See details below. 🌟 Medinvest1 Kyle: Another fantastic project with Rastegar Property Company for the development of 320 acres in Kyle TX. 🌟 Medinvest Income Fund: Consistent short-term cash flow with a 10% preferred annual return, backed by a portfolio of real estate assets. DM me if you would like to learn more about any of these opportunities. #realestateinvestment #investmentopportunities #rastegarpropertycompany #doctorinvestor

amazingly good application of this technology.

Braveheart Investment Group PLC (AIM:BRH) has confirmed it has written down the values of its two main holdings - instrument company Paraytec and Kirkstall, which has developed technology to replace animals in medical testing. "The board believes that, with time, both Kirkstall and Paraytec could have the potential to increase in value and provide exit opportunities for the company, but it is prudent to write the values down to zero at the current time," the company said in commentary accompanying its prelims. As a result of these adjustments, the company posted a pre-tax loss for the 12 months ending March 31 of £8.19 million. It exited the year with £1.74 million of cash and owns investments worth £1.65 million. Investors were told Braveheart had implemented a "range of actions to rationalise the company's cost base and to conserve cash".     More at #Proactive #ProactiveInvestors http://ow.ly/1n4r105xCgm

The spotlight on early-stage life sciences companies continues to intensify, fueled by heightened investor interest and a surge in M&A activity within the space. In "The Relationship between Funding and Exit Paths," MABA Founder Yaniv Sneor sits down with TEN Capital Network to delve into the intricate dynamics shaping the journey of young life science ventures. With a focus on potential exit strategies, Yaniv provides invaluable insights into how these decisions not only guide the path forward but significantly influence funding considerations. https://lnkd.in/e54xpNPD #LifeSciences #AngelInvesting #MABA 

Effortless Investing with Astravest! Say goodbye to stress! With Astravest, investing is a breeze. Join our online community to enjoy exclusive access to market hours and investment insights Start Now. Link in Bio #chooseastravest #investment #commodities #timetobuildwealth